Winelandthomson Adventures Inc
Total Consideration
$30.0M
Purchase-Price Allocation
Goodwill
$17.0M
Intangibles
$8.6M
3 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 0.40% | -0.80% | -0.30% | -2.10% | -1.40% | -0.50% |
| Foreign Rate Differential | -10.50% | -15.20% | -16.60% | -17.10% | -32.70% | — |
| Other Adjustments | 0.20% | 0.80% | -0.70% | 0.70% | -1.30% | -0.70% |
| SBC (Nondeductible) | 0.00% | — | — | — | — | — |
| Nondeductible Expenses | -0.10% | — | — | — | — | — |
| Valuation Allowance Change | -2.20% | -4.10% | -9.40% | -6.80% | 7.20% | -6.50% |
| Tax Law Change | — | — | — | 0.00% | 0.00% | 4.60% |
| Effective Tax Rate | 8.90% | 1.70% | -6.00% | -8.30% | -12.40% | -11.40% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$9.8M | −$2.0M | $6.1M | $3.1M | $3.1M | $2.5M |
| Income Taxes Paid (Cash) | $700.0K | $98.0K | $309.0K | $711.0K | $319.0K | $3.2M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$30.0M
Purchase-Price Allocation
Goodwill
$17.0M
Intangibles
$8.6M
Purchase-Price Allocation
Intangibles
$3.3M
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).